Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models.

Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, Liang TJ.

Hepatology. 2011 Jan;53(1):32-41. doi: 10.1002/hep.23985. Epub 2010 Oct 26.

2.

Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.

Watanabe T, Sugauchi F, Tanaka Y, Matsuura K, Yatsuhashi H, Murakami S, Iijima S, Iio E, Sugiyama M, Shimada T, Kakuni M, Kohara M, Mizokami M.

Gut. 2013 Sep;62(9):1340-6. doi: 10.1136/gutjnl-2012-302553. Epub 2012 Nov 7.

3.

Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C.

Rotman Y, Noureddin M, Feld JJ, Guedj J, Witthaus M, Han H, Park YJ, Park SH, Heller T, Ghany MG, Doo E, Koh C, Abdalla A, Gara N, Sarkar S, Thomas E, Ahlenstiel G, Edlich B, Titerence R, Hogdal L, Rehermann B, Dahari H, Perelson AS, Hoofnagle JH, Liang TJ.

Gut. 2014 Jan;63(1):161-9. doi: 10.1136/gutjnl-2012-303852. Epub 2013 Feb 8.

4.
6.

Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.

Qashqari H, Al-Mars A, Chaudhary A, Abuzenadah A, Damanhouri G, Alqahtani M, Mahmoud M, El Sayed Zaki M, Fatima K, Qadri I.

Infect Genet Evol. 2013 Oct;19:113-9. doi: 10.1016/j.meegid.2013.06.025. Epub 2013 Jul 5. Review.

PMID:
23831932
7.

Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin.

Younossi ZM, Baranova A, Afendy A, Collantes R, Stepanova M, Manyam G, Bakshi A, Sigua CL, Chan JP, Iverson AA, Santini CD, Chang SY.

Hepatology. 2009 Mar;49(3):763-74. doi: 10.1002/hep.22729.

PMID:
19140155
8.

Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8.

Tokumoto Y, Hiasa Y, Uesugi K, Watanabe T, Mashiba T, Abe M, Kumagi T, Ikeda Y, Matsuura B, Onji M.

J Infect Dis. 2012 Apr 1;205(7):1121-30. doi: 10.1093/infdis/jis025. Epub 2012 Feb 21.

9.

Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response.

Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, Schweigler LM, Theodore D, Zacks SL, Liang TJ, Fried MW.

Hepatology. 2007 Nov;46(5):1548-63.

10.

Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo.

Pan Q, de Ruiter PE, Metselaar HJ, Kwekkeboom J, de Jonge J, Tilanus HW, Janssen HL, van der Laan LJ.

Hepatology. 2012 Jun;55(6):1673-83. doi: 10.1002/hep.25562. Epub 2012 Apr 18.

PMID:
22213147
11.

Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C.

Dill MT, Makowska Z, Duong FH, Merkofer F, Filipowicz M, Baumert TF, Tornillo L, Terracciano L, Heim MH.

Gastroenterology. 2012 Sep;143(3):777-86.e1-6. doi: 10.1053/j.gastro.2012.05.044. Epub 2012 Jun 4.

PMID:
22677194
12.
13.

PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis C.

Markova AA, Mihm U, Schlaphoff V, Lunemann S, Filmann N, Bremer B, Berg T, Sarrazin C, Zeuzem S, Manns MP, Cornberg M, Herrmann E, Wedemeyer H.

PLoS One. 2014 Apr 21;9(4):e94512. doi: 10.1371/journal.pone.0094512. eCollection 2014.

14.

Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.

Hofmann WP, Chung TL, Osbahr C, Susser S, Karey U, Mihm U, Welsch C, Lötsch J, Sarrazin C, Zeuzem S, Herrmann E.

Antivir Ther. 2011;16(5):695-704. doi: 10.3851/IMP1821.

PMID:
21817191
15.

Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.

Plumlee CR, Lazaro CA, Fausto N, Polyak SJ.

Virol J. 2005 Dec 2;2:89.

16.

Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.

Yano Y, Seo Y, Miki A, Saito M, Kato H, Hamano K, Oya M, Ouchi S, Fujisawa T, Yamada H, Yamashita Y, Tani S, Hirohata S, Yoon S, Kitajima N, Kitagaki K, Kawara A, Nakashima T, Yu H, Maeda T, Azuma T, El-Shamy A, Hotta H, Hayashi Y; Kobe Hepatitis Therapeutic Group.

Int J Mol Med. 2012 Nov;30(5):1048-52. doi: 10.3892/ijmm.2012.1093. Epub 2012 Aug 9.

PMID:
22899224
17.

Pegylated interferon-α induced hypoferremia is associated with the immediate response to treatment in hepatitis C.

Ryan JD, Altamura S, Devitt E, Mullins S, Lawless MW, Muckenthaler MU, Crowe J.

Hepatology. 2012 Aug;56(2):492-500. doi: 10.1002/hep.25666. Epub 2012 Jun 11.

PMID:
22334511
18.

Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.

Naggie S, Osinusi A, Katsounas A, Lempicki R, Herrmann E, Thompson AJ, Clark PJ, Patel K, Muir AJ, McHutchison JG, Schlaak JF, Trippler M, Shivakumar B, Masur H, Polis MA, Kottilil S.

Hepatology. 2012 Aug;56(2):444-54. doi: 10.1002/hep.25647. Epub 2012 Jul 2.

19.

Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.

Sede M, Laufer N, Ojeda D, Gun A, Cahn P, Quarleri J.

Arch Virol. 2013 Sep;158(9):1907-15. doi: 10.1007/s00705-013-1687-6. Epub 2013 Apr 4.

PMID:
23553458
20.

Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication.

Metz P, Dazert E, Ruggieri A, Mazur J, Kaderali L, Kaul A, Zeuge U, Windisch MP, Trippler M, Lohmann V, Binder M, Frese M, Bartenschlager R.

Hepatology. 2012 Dec;56(6):2082-93. doi: 10.1002/hep.25908. Epub 2012 Oct 14.

PMID:
22711689
Items per page

Supplemental Content

Write to the Help Desk